Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScRNA for pansclerotic morphea lesional

ABSTRACT: scRNA for pansclerotic morphea lesional

PROVIDER: PRJNA983843 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24920274_1.fastq.gz	Fastqsanger.gz
	SRR24920274_2.fastq.gz	Fastqsanger.gz
	SRR24920275_1.fastq.gz	Fastqsanger.gz
	SRR24920275_2.fastq.gz	Fastqsanger.gz
	SRR24920276_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 14

Similar Datasets

Analysis of microarray data of lesional and unaffected skin from morphea patients

Project description:Analysis of microarray data of lesional and unaffected skin from morphea patients

2023-06-01 | GSE153011 | GEO

scRNA for pansclerotic morphea lesional

Project description:We compared the PSM lesional/non-lesional skin samples with the control skin in the analysis.

2023-10-19 | GSE234987 | GEO

Gene expression signatures in inflammatory and sclerotic morphea skin and blood distinguishes morphea from systemic sclerosis

Project description:Morphea is an inflammatory disorder of the skin and soft tissue characterized by fibrosis that has been likened to systemic sclerosis (SSc). We sought to capture the molecular heterogeneity of morphea by examining lesional skin gene expression and blood biomarkers, and compare the gene expression profiles with those from SSc lesional and site matched non lesional skin, as well as sera obtained from adult patients with untreated morphea. We found the morphea transcriptome is dominated by IFNg-mediated Th1 immune dysregulation, with relative paucity of pathways associated with fibrosis. These results were mirrored when morphea gene expression profiles were compared with SSc. Interestingly, expression profiles of morphea skin samples clustered with the SSc inflammatory subset and distinct from the SSc fibro-proliferative subset. Unaffected morphea skin also differed from unaffected SSc skin in that it did not exhibit pathological gene expression signatures. Examination of downstream IFNg-mediated chemokines, CXCL9 and CXCL10, revealed increased transcription in the skin but not in sera. While elevated serum CXCL9 proteins quantified by ELISA were associated with active disease and widespread cutaneous disease. Taken together, these results indicate that inflammatory and sclerotic morphea is a skin directed process characterized by Th1 immune mediated dysregulation, which contrasts with fibrotic signatures and systemic transcriptional changes associated with SSc. The association of circulating CXCL9 concentration with clinical activity and burden of skin disease supports its potential as a readily accessible biomarker.

2025-04-13 | GSE201405 | GEO

Analysis of microarray data of lesional and unaffected skin from morphea patients

Project description:Analysis of microarray data of lesional and unaffected skin from morphea patients

| PRJNA641360 | ENA

Esoinophilic fasciitis and morphea share gene signatures of inflammatory cell death, self-DNA recognition, and JAK/STAT signaling

Project description:The pathogenesis of eosinophilic fasciitis (EF) and morphea is poorly understood. We analyzed skin biopsies from EF and morphea patients compared to adult healthy skin (HS) using gene expression profiling, Ingenuity Pathway Analysis, and immunostaining. EF gene expression showed significant overlap with morphea. 51/61 differentially expressed genes (DEG), 80/99 canonical pathways, and 40/51 upstream regulators were shared in EF and morphea. Both conditions exhibited robust T cell activation and cytotoxic signatures despite their pauci-inflammatory histological appearance, suggesting small numbers of T cells may drive injury, inflammation, and fibrosis. EF and morphea shared signatures of necroptosis, self-DNA recognition, cGAS/STING activation, induction of types I, II, and III interferon signaling, and fibrosis. Seven JAK/STAT molecules were significantly upregulated in EF and nine were upregulated in morphea. Compared to HS, TYK2 was the most significant JAK molecule upregulated in EF (p=0.0007) and morphea (p=0.0002). Immunostaining demonstrated activated interferon-related molecules JAK1 and STAT1 in T cells, dendritic cells, and macrophages in both diseases. This study identifies shared molecular mechanisms of EF and morphea and demonstrates strong pathophysiologic similarities between the two diseases. Our findings indicate that targeted inhibition of JAK/STAT molecules and mediators of necroptosis may be beneficial in treating these fibrotic diseases.

2025-05-19 | GSE278882 | GEO

Scleroderma Morphea Normal Fibroblasts

Project description:Fibroblast were isolated from either back or forearm punch biopsies taken by Dr. Kari Connolly(UCSF) from either normal control patients, patients with a diagnosis of Systemic Sclerosis with Diffuse Scleroderma and patients with a diagnosis of morphea. Scleroderma fibroblast were grown to confluence, media was changed and the RNA prepared from the cells 48 hrs later (to avoid serum responsive genes). A disease state experiment design type is where the state of some disease such as infection, pathology, syndrome, etc is studied. User Defined

2005-12-20 | E-GEOD-3886 | biostudies-arrayexpress

Scleroderma Morphea Normal Fibroblasts

2005-12-21 | GSE3886 | GEO

Microarray data vitiligo patients lesional and non-lesional skin

Project description:lesional and non-lesional skin from vitiligo patients

2016-11-01 | GSE75819 | GEO

Effect of autologous fat grafting on Localized Scleroderma (morphea)

Project description:Localized scleroderma (LoS), or morphea, refers to a group of rare autoimmune connective tissue diseases. Autologous fat grafting was able to correct volume loss in patients with LoS to improve facial disfigurement.However, whether it could exert a positive effect on reversing skin sclerosis remains unclear.

2023-11-20 | GSE247804 | GEO

Gene expression profiling in psoriatic lesional and non-lesional skin [brodalumab treatment]

Project description:To explore the psoriasis phenotype and pathways involved in psoriasis, we characterized gene expression in lesional and non-lesional skin from psoriasis patients. Furthermore, we explored the effects of various doses of brodalumab on lesional skin over time. From each of the 25 psoriasis patients, we obtained two pre-dose biopsies, one from a lesion and the other from non-lesional skin in the same general body geography, and two post-dose biopsies. Total RNA was extracted from 6mm punch biopsies that were split in half. A total of 99 samples were run on Affymetrix HU133 Plus 2.0 microarrays. There was no paired non-lesional sample for 'T_lesional_pre-dose' (skn55789).

2014-03-31 | E-GEOD-53552 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data